Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025
DOI: 10.1016/j.bbcan.2025.189274 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025. Verfasst von Monika Granica und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; Department of Immunology, Mossakowski Medical Research Institute Polis…. Hauptthemen laut MEDLINE: Neoplasms, B7-H1 Antigen, Immunotherapy, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Mossakowski Medical Research Institute Polish Academy of Sciences, National Science Centre Poland.
Abstract (Originalsprache)
The modulation of the N-glycosylation status in immune checkpoints, particularly the PD-1/PD-L1 axis, has emerged as a promising approach to enhance cancer immunotherapies. While immune checkpoint inhibitors (ICIs) targeting PD-1 and PD-L1 have achieved significant clinical success, recent studies highlight the critical role of N-glycosylation in regulating their expression, stability, and function. Alterations in N-glycosylation might affect the efficacy of ICIs by modulating the interactions between immune checkpoints and antibodies used in therapy. This review focuses on the glycosylation of PD-1 and its ligands PD-L1 and PD-L2, examining how N-glycans influence immune responses and contribute to immune evasion by tumors. It explores innovative strategies to modulate glycosylation in tumor and immune cells, including the use of N-glycosylation inhibitors and novel genetic manipulation techniques. Understanding the interplay between N-glycosylation and immune checkpoint functions is essential for optimizing immunotherapy outcomes and overcoming therapeutic resistance in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; Department of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences, 02-106 Warsaw, Poland; Doctoral School, Medical…
- Department of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences, 02-106 Warsaw, Poland.
- Department of Medical Physiology, Faculty of Health Sciences, Jagiellonian University Medical College, 31-126 Krakow, Poland; Center for the Development of Therapies for Civilization and Age-Related Diseases, Jagielloni…
- Department of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences, 02-106 Warsaw, Poland. Electronic address: agraczyk@imdik.pan.pl.
Förderung
- Mossakowski Medical Research Institute Polish Academy of Sciences
- National Science Centre Poland
Zitieren
APA
Granica, M., Laskowski, G., Link-Lenczowski, P., & Graczyk-Jarzynka, A. (2025). Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189274
Vancouver
Granica M, Laskowski G, Link-Lenczowski P, Graczyk-Jarzynka A. Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. doi:10.1016/j.bbcan.2025.189274
BibTeX
@article{Granica2025,
author = {Granica, Monika and Laskowski, Gustaw and Link-Lenczowski, Paweł and Graczyk-Jarzynka, Agnieszka},
title = {Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2025},
doi = {10.1016/j.bbcan.2025.189274}
}
EUVIMED